Can a diabetes drug help the brain heal after a stroke?

NCT ID NCT07734792

Not yet recruiting Disease control Sponsor: yifang zhu Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether tirzepatide, a drug approved for diabetes and obesity, can improve recovery in people who have had a severe stroke caused by a large artery blockage. Participants receive two injections of tirzepatide—one before a clot-removal procedure and another a week later—or standard care alone. The goal is to see if the drug reduces brain injury and helps patients regain independence 90 days after the stroke.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (a drug that activates GLP-1 and GIP pathways, also used for diabetes and obesity)
What this could lead to: If it works, tirzepatide could become a new treatment to reduce disability after a severe stroke, helping more people regain independence.
What could go wrong: This is an early-to-mid-stage trial, so the drug may not improve recovery and could cause side effects like nausea or low blood sugar. Results may not apply to all stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE (AIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE (AIS)

Contacts and locations

Locations

The Second Afliated Hospital of SooChow University

Suzhou, Jiangsu, 215004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.